Devonyu/Istock via Getty Images
Johnson and Johnson (New York:JnjOn Saturday, it announced the preliminary results of a group of patients who were part of the Sunrise-1 Phase 2B experience for Tar-200, an internal launch system for GMCitabine chemotherapy targeting certain forms of bladder cancer.
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/840227576/image_840227576.jpg?io=getty-c-w750
Source link